Company Peak Bio, Inc.

Equities

PKBO

US70470P1084

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 01:11:26 2024-05-30 pm EDT			5-day change	1st Jan Change
0.0086 ^USD	-.--%		-.--%	-95.41%

Mar. 05	Akari Therapeutics, Plc entered into a definitive agreement to acquire Peak Bio, Inc..	CI
Feb. 16	Peak Bio, Inc. announced that it has received $2.238 million in funding	CI

Peak Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on commercializing therapeutics that aim to improve and address unmet medical needs for patients with inflammatory, rare and specialty diseases and cancer. The Companyâs lead product candidate, PHP-303, is a small molecule, fifth generation, phase II clinical-ready neutrophil elastase (NE) inhibitor (NEI). PHP-303 is an oral, once daily, 0.65 nanomolar, selective, small molecule reversible inhibitor of NE designed to inhibit its bioactive form that the Company is developing for the treatment of alpha-1 antitrypsin deficiency (AATD), a genetic disorder that may result in lung disease or liver disease and, potentially, acute respiratory distress syndrome (ARDS). The Companyâs advanced platform in oncology utilizes its toxin, PH-1 or Thailanstatin, to generate a pipeline of antibody-drug-conjugates (ADC) product candidates that are differentiated from traditional ADC-based therapies.

Number of employees: 21

USD in Million	2021	Weight	2022	Weight	Delta
Innovative Therapies 100.0 %	-	-	1	100.0 %	-

USD in Million	2021	Weight	2022	Weight	Delta
United States 100.0 %	0	nan %	1	100.0 %	-

Managers	Title	Age	Since
Stephen LaMond CEO	Chief Executive Officer	-	22-10-31
Timothy Cunningham DFI	Director of Finance/CFO	62	22-10-31
Satyajit Mitra BRD	Director/Board Member	50	22-10-31

Members of the board	Title	Age	Since
James Neal BRD	Director/Board Member	68	22-10-31
Ho Young Huh CHM	Chairman	54	22-10-31
Michael Friedman BRD	Director/Board Member	-	23-08-24
Stephen LaMond CEO	Chief Executive Officer	-	22-10-31
David Rosenberg BRD	Director/Board Member	50	22-10-31
Satyajit Mitra BRD	Director/Board Member	50	22-10-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	21,903,843	13,348,989 ( 60.94 %)	0	60.94 %

Name	Equities	%	Valuation
Ho Young Huh 39.97 %	8,755,682	39.97 %	2 M $
SBI INVESTMENT KOREA CO., LTD. 15.77 %	3,453,889	15.77 %	649 331 $
David Rosenberg 1.779 %	389,630	1.779 %	73 250 $
Phillip Frost 0.4565 %	100,000	0.4565 %	18 800 $
Stephen LaMond 0.0906 %	19,850	0.0906 %	3 732 $
Michael Friedman 0.0853 %	18,692	0.0853 %	3 514 $
James Neal 0.000000 %	0	0.000000 %	- $
Satyajit Mitra 0.000000 %	0	0.000000 %	- $
Cohen & Company Financial Management LLC 0.000000 %	0	0.000000 %	- $

Peak Bio, Inc.

4900 Hopyard Road Suite 100

94588, Pleasanton

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
PEAK BIO, INC.	-95.41%	199K
MODERNA, INC.	+46.19%	55.7B
LONZA GROUP AG	+39.81%	39.91B
IQVIA HOLDINGS INC.	-6.14%	39.57B
CELLTRION, INC.	-6.65%	28.16B
ICON PUBLIC LIMITED COMPANY	+12.33%	26.3B
ALNYLAM PHARMACEUTICALS, INC.	-21.78%	18.94B
MEDPACE HOLDINGS, INC.	+28.38%	12.17B
UNITED THERAPEUTICS CORPORATION	+24.18%	12.12B
BIO-TECHNE CORPORATION	-0.35%	12.12B

Other Biotechnology & Medical Research